NASDAQ:LMNXLuminex Stock Price, Forecast & News

Luminex's stock was trading at $27.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, LMNX stock has increased by 34.3% and is now trading at $36.40.
View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Luminex in the last year. There are currently 1 sell rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Luminex.

Luminex is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020.
View our earnings forecast for Luminex.

Luminex will be holding an earnings conference call on Tuesday, August 4th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Luminex Co. (NASDAQ:LMNX) announced its earnings results on Monday, May, 4th. The medical instruments supplier reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02. The medical instruments supplier earned $90.40 million during the quarter, compared to analysts' expectations of $82.30 million. Luminex had a negative return on equity of 1.25% and a negative net margin of 1.81%. The company's quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the company earned $0.07 EPS.
View Luminex's earnings history.

Luminex declared a quarterly dividend on Tuesday, May 26th. Investors of record on Thursday, June 18th will be paid a dividend of $0.09 per share on Thursday, July 9th. This represents a $0.36 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date of this dividend is Wednesday, June 17th.
View Luminex's dividend history.

Luminex updated its second quarter 2020 Pre-Market earnings guidance on Wednesday, July, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109-110 million, compared to the consensus revenue estimate of $106.25 million.

2 analysts have issued 12 month target prices for Luminex's shares. Their forecasts range from $21.00 to $32.00. On average, they anticipate Luminex's share price to reach $26.50 in the next twelve months. This suggests that the stock has a possible downside of 27.2%.
View analysts' price targets for Luminex.

Media coverage about LMNX stock has been trending negative on Monday, according to InfoTrie. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Luminex earned a daily sentiment score of -2.9 on InfoTrie's scale. They also gave media stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future.
View the latest news about Luminex.

Luminex saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 5,560,000 shares, an increase of 39.0% from the June 15th total of 4,000,000 shares. Based on an average daily trading volume, of 753,600 shares, the short-interest ratio is currently 7.4 days. Currently, 13.1% of the company's shares are sold short.
View Luminex's Current Options Chain.

Some companies that are related to Luminex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), Waters (WAT), BIO-TECHNE (TECH), Charles River Laboratories Intl. (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Luminex investors own include Baidu (BIDU), NVIDIA (NVDA), Crispr Therapeutics (CRSP), Cisco Systems (CSCO), Inovio Pharmaceuticals (INO), Square (SQ), Verizon Communications (VZ), AbbVie (ABBV), American Express (AXP) and Micron Technology (MU).

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

Luminex's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Copeland Capital Management LLC (1.83%), Cowen Prime Services LLC (0.37%), Robeco Institutional Asset Management B.V. (0.30%), Envestnet Asset Management Inc. (0.23%), Mackay Shields LLC (0.16%) and Assenagon Asset Management S.A. (0.15%). Company insiders that own Luminex stock include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers and Richard W Rew II.
View institutional ownership trends for Luminex.

LMNX stock was sold by a variety of institutional investors in the last quarter, including Cowen Prime Services LLC, Bridge City Capital LLC, Dupont Capital Management Corp, UBS Group AG, Banque Cantonale Vaudoise, and Creative Planning. Company insiders that have sold Luminex company stock in the last year include Charles J Collins, G Walter Loewenbaum II, Nachum Shamir, Nancy Fairchild, Randall Myers, and Richard W Rew II.
View insider buying and selling activity for Luminex.

LMNX stock was bought by a variety of institutional investors in the last quarter, including Copeland Capital Management LLC, Robeco Institutional Asset Management B.V., Assenagon Asset Management S.A., Mackay Shields LLC, Envestnet Asset Management Inc., Hussman Strategic Advisors Inc., Strs Ohio, and Wakefield Asset Management LLLP. Company insiders that have bought Luminex stock in the last two years include G Walter Loewenbaum II, and Nachum Shamir.
View insider buying and selling activity for Luminex.

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of LMNX stock can currently be purchased for approximately $36.40.

Luminex has a market capitalization of $1.67 billion and generates $334.64 million in revenue each year. The medical instruments supplier earns $-3,840,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis. Luminex employs 1,247 workers across the globe.

The official website for Luminex is www.luminexcorp.com.

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]